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A Ab bs st tr ra ac ct t
The BRCA1 4153delA allele is frequently referred to as the Russian founder mutation, as it was initially detected in
several cancer families from Moscow. Our earlier studies have demonstrated 1% occurrence of BRCA1 4153delA
heterozygosity in familial and/or early-onset and/or bilateral Russian breast cancer (BC) patients. Since literature
data suggest that the 4153delA variant is more associated with ovarian cancer (OC) than with BC, we expected to
reveal a highly elevated frequency of this genotype in Russian ovarian cancer series. However, real-time allele-specific
PCR genotyping has detected only two BRCA1 4153delA carriers out of 177 unselected OC patients (1.1%). Both
these carriers were early-onset and had serous carcinomas of grade 3. Thus, our study supports neither the Russian
origin of BRCA1 4153delA mutation, nor its selectivity towards ovarian versus breast cancer predisposition.
I In nt tr ro od du uc ct ti io on n
Ovarian cancer (OC) affects approximately 1 out of
70 women during their lifetime and is regarded as the
most lethal gynaecological malignancy. Early ovarian
cancer does not usually cause symptoms; therefore it can
be detected only through prophylactic medical check.
Furthermore, even the combination of sophisticated
technologies, such as ultrasound examination, magnetic
resonance imaging, and CA-125 antigen measurement,
does not fully guarantee timely OC diagnosis [1-3]. 
A significant portion of OC cases arise due to the
presence of a germline mutation in the BRCA1 or BRCA2
gene. Estimates of occurrence of BRCA mutations in
unselected OC cases vary from 3% to 35% (reviewed in
[4]). Surprisingly, the occurrence of BRCA defects in
random series of OC is similar to that observed in high-
-risk categories of breast cancer (BC), such as familial
and/or early-onset and/or bilateral cases of the disease.
Therefore, the mere fact of ovarian cancer diagnosis
appears to justify BRCA testing.
Complete analysis of BRCA1 and BRCA2 genes
cannot be used yet on a large scale due to the high cost
of appropriate laboratory procedures. Fortunately, in some
ethnic groups and geographic regions the BRCA mutation
spectrum is limited to a small number of so-called founder
mutations [5]. For example, only a few simple PCR tests
allow most of the BRCA carriers in Israel, Iceland, Poland,
Russia, etc to be revealed. One of these founder
mutations is BRCA1 4153delA, which was originally
described in Russian cancer families [6]. This mutation
also occurs in Poland, Latvia, Lithuania and Belarus 
[7-13]. Some evidence suggest that this mutation is more
associated with ovarian than with breast cancer. In
particular, the initial study of Gayther et al. [6], which
identified three 4153delA mutations in 19 families, wasH He er re ed diit ta ar ry y C Ca an nc ce er r iin n C Clliin niic ca all P Pr ra ac ct tiic ce e 2006; 4(4) 194
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specifically focused on ovarian cancer pedigrees.
Furthermore, a series of investigations performed by
Lubinski and associates demonstrated a noticeable
occurrence of BRCA1 4153delA in ovarian but not in
breast cancer patients. For example, a study of unselected
Polish patient series has revealed 8/364 (2.2%) carriers
in OC, but only 1/2012 (0.05%) in BC cases [4, 11].
We have recently tested 302 breast cancer patients
characterized by family history and/or early-onset and/or
bilaterality, and detected 3 (1%) 4153delA allele carriers
[Sokolenko et al., manuscript submitted]. Based on the
apparent Russian origin of this mutation [5, 6] as well as
on its probable specificity towards OC predisposition [4,
11, 14], we hypothesized that unselected ovarian cancer
cases from Russia will be characterized by highly elevated
occurrence of the 4153delA variant. 
M Ma at te er ri ia al ls s a an nd d m me et th ho od ds s
P Pa at ti ie en nt ts s a an nd d D DN NA A i is so ol la at ti io on n
The study included 177 ovarian cancer patients,
who underwent surgical treatment in N.N. Petrov
Institute of Oncology, St. Petersburg, Russia. Patients’
characteristics are described in Table 1. Archived
specimens of the excised normal tissues were used as
a source of DNA. DNA isolation was performed as
described in [15]. Briefly, tissue sections were
deparaffinized in 2 changes of xylene, and then boiled
for 5 min. in 100 µl of the lysis buffer (10 mM Tris-HCl,
pH 8.3; 1mM EDTA; 0.5% NP-40, 0.5% Tween 20).
Proteinase K was subsequently added up to the
concentration of 500 µg/ml. Protein digestion was
done overnight at 60°C. Next, the tissue lysates were
boiled again in order to inactivate proteinase K. Finally,
samples were diluted to 1:10 with water in order to
decrease the concentration of PCR inhibitors. 
B BR RC CA A1 1 4 41 15 53 3d de el lA A g ge en no ot ty yp pi in ng g
BRCA1 4153delA was detected using SYBR Green
based real-time allele-specific PCR. Primers were 
5’-GACTGCAAATACAAACACCCA – 3’ (common),
5’-AGCCCGTTCCTCTTTCTTC – 3’ (specific for the
wild-type allele), and 5’-AGCCCGTTCCTCTTTCTCA –
3’ (specific for the 4153delA mutation). PCR reactions
were carried out for 50 cycles (95°C for 35 sec., 62°C
for 60 sec., 72°C for 60 sec.) in the iCycler iQ Real Time
Detection System (Bio-Rad). 10 µl of PCR cocktail
included 1 µl diluted archival tissue lysate, 1 unit heat-
-activated Taq DNA polymerase, 1
X PCR buffer (pH 8.3),
2.5 mM MgCl2, 200 µM dNTP , 0.5 µM each primer, and
0.5
X SYBR Green I. The specificity of the 134-bp PCR
product was confirmed by melting curve analysis. In order
to control the accuracy of the real-time genotyping, 
a conventional gel-based allele-specific PCR (35 cycles
in the same conditions) was applied to all mutation-
-positive samples as well as to some randomly selected
mutation-negative DNA specimens. 
R Re es su ul lt ts s
An example of the detection of BRCA1 4153delA
mutation is presented in fig. 1. As seen in this figure,
allele-specific PCR allowed reliable discrimination
between mutated and wild-type alleles in both real-
time and conventional format.
An analysis of 177 unselected ovarian cancer cases
allowed only two 4153delA mutation carriers (1.1%) to
be revealed. Both cases were early onset (39 and 42
years, respectively), and had identical morphological
characteristics (T3NxM0, serous histology, grade 3).
Records on family history in the present data set were
incomplete and therefore not considered in the study
analysis; nevertheless, one of the BRCA1 4153delA
carriers reported an ovarian cancer in her grandmother.
Since the observed frequency of the 4153delA allele
was lower than expected, part of the DNA samples was
T Ta ab bl le e 1 1. . Clinical characteristics of ovarian carcinoma patients
Mean age  52.2 years
Age range 21-87 years
Age distribution 
£40 years 24 (13.6%)
41-60 years 104 (58.8%)
‡61 years  48 (27.1%)
Non-informative 1 (0.6%)
T status
T=1 24 (13.6%)
T>1 151 (85.3%)
Non-informative 2 (1.1%)
N status
N=0 61 (34.5%)
N=1 44 (24.9%)
Nx 70 (39.5%)
Non-informative 2 (1.1%)
Tumour differentiation
Grade 1 19 (10.7%)
Grade 2 47 (26.6%)
Grade 3 94 (53.1%)
Non-informative 17 (9.6%%)
Histology 
Serous adenocarcinoma 144 (81.4%)
Mucinous adenocarcinoma 6 (3.4%)
Adenocarcinoma, unspecified 21 (11.9%)
Other 6 (3.4%)
Total 177 (100%)H He er re ed diit ta ar ry y C Ca an nc ce er r iin n C Clliin niic ca all P Pr ra ac ct tiic ce e 2006; 4(4) 195
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F Fi ig g. . 1 1. . BRCA 4153delA genotyping. Both wild-type and mutation-specific primers produce the PCR fragment for the heterozygote (left),
while only one product is detected upon the analysis of normal DNA sample (right). Identical results are obtained by real-time (top) and
conventional (bottom) allele-specific PCR
genotyped for BRCA1 5382insC mutation. BRCA1
5382insC occurs in up to 10% of familial and/or early-
onset and/or bilateral breast cancer patients in Russia
[16]; therefore it is likely to be frequent in ovarian
cancers as well. An analysis of the 5382insC variant
was performed as a positive control for 21 OC
samples from our series, and 5 mutations (23.8%) were
revealed. Therefore we conclude that the low frequencyH He er re ed diit ta ar ry y C Ca an nc ce er r iin n C Clliin niic ca all P Pr ra ac ct tiic ce e 2006; 4(4) 196
of BRCA1 4153delA is not an artefact of the study
design, but reflects the true contribution of this allele
in Russian ovarian cancer.
D Di is sc cu us ss si io on n
This study failed to reveal elevated incidence of
BRCA1 4153delA mutation in unselected Russian
patients suffering from ovarian cancer. BRCA1 4153delA
was detected in several East European countries;
however, its frequency significantly varies even within
closely located geographic regions [8, 9, 11, 12]. The
uneven distribution of 4153delA allele carriers may
reflect a relatively recent origin of this genetic variant.
The data obtained in the present study are strikingly
similar to the results of the analysis of Russian familial
and/or early-onset and/or bilateral breast cancer
[Sokolenko et al., manuscript submitted]. In particular,
we observed moderate frequency of BRCA1 4153delA
mutation (2/177 (1.1%) for OC and 3/302 (1.0%) for
BC), but highly elevated occurrence of the BRCA1
5382insC variant (5/21 (23.8%) for OC and 29/302
(9.6%) for BC). Nonetheless, given the presumably high
penetrance of BRCA1 truncating mutations, even the
frequency of 1% in cancer patients seems to be sufficient
justification for extended genetic testing. Therefore, we
believe that BRCA1 4153delA mutation has to be
included in the array of tests aimed at revealing cancer
syndrome carriers among subjects of Russian origin.
In conclusion, this study supports neither the Russian
origin of BRCA1 4153delA mutation [5, 6] nor its
selectivity towards ovarian versus breast cancer
predisposition [4, 11, 14]. However, the 4153delA
variant does make a moderate contribution to breast
and ovarian cancer incidence in Russia; thus it has to
be considered in clinical practice.
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